尽管亏损，Rapport Therapeutics 仍超出盈利预期，但股价因成交量强劲而上涨。 Rapport Therapeutics beat earnings estimates despite a loss, stock rose on strong volume.

报告第二季度收入(RAPP)为每股0.71美元,损失额估计为0.06美元。 Rapport Therapeutics (RAPP) reported second-quarter earnings with a loss of $0.71 per share, beating estimates by $0.06. 股票在星期五上涨0.30美元至25.66美元,交易额高于平均水平。 The stock rose $0.30 to $25.66 on Friday, with above-average trading volume. 以波士顿为基地的临床阶段生物技术侧重于CNS疾病,市场上限为9.36亿美元,P/E比率为负数。 The Boston-based clinical-stage biotech, focused on CNS disorders, has a market cap of $936 million and a negative P/E ratio. 分析师维持了“机动购买”共识,平均目标是46.50美元,而一些公司则将目标提高到80美元。 Analysts maintain a "Moderate Buy" consensus with an average target of $46.50, while some firms raised targets to $80.00. 该公司继续推进其牵头候选人RAP-219,以进行重点癫痫治疗,但目前没有红利。 The company continues to advance its lead candidate, RAP-219, for focal epilepsy, with no current dividend. 报告了内部销售情况,但机构所有权仍然强劲。 Insider sales were reported, but institutional ownership remains strong.